NCT06598839View on ClinicalTrials.gov

Immuno-effect of Tα1 for Stage I NSCLC

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

December 30, 2025

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Thymosin Alpha1

subcutaneous injection of Tα1, 1.6mg each time, biw, for 3 months

Trial Locations (1)

100021

RECRUITING

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Yousheng Mao

OTHER